BMY Earnings
Latest Revenue13.0B
Latest Net Income3.3B
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $1.62 | 13.0B | 3.3B | +5.7% | +153.1% |
| Q1 2026 | $1.31 | 11.5B | 2.7B | +2.6% | +8.3% |
| Q4 2025 | $0.53 | 12.5B | 1.1B | +1.3% | +1,225.0% |
| Q3 2025 | $1.08 | 12.2B | 2.2B | +2.8% | +80.0% |
| Q2 2025 | $0.64 | 12.3B | 1.3B | +0.6% | -22.9% |
| Q1 2025 | $1.21 | 11.2B | 2.5B | -5.6% | +120.5% |
| Q4 2024 | $0.04 | 12.3B | 76.0M | +7.5% | -95.4% |
| Q3 2024 | $0.60 | 11.9B | 1.2B | +8.4% | -36.2% |
| Q2 2024 | $0.83 | 12.2B | 1.7B | — | — |
| Q1 2024 | -$5.89 | 11.9B | -11908000000 | — | — |
| Q4 2023 | $0.87 | 11.5B | 1.8B | — | — |
| Q3 2023 | $0.94 | 11.0B | 1.9B | — | — |
Bristol-Myers Squibb (BMY) — Earnings